Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study

被引：0
|
作者：
S J Isakoff
D Wang
M Campone
A Calles
E Leip
K Turnbull
N Bardy-Bouxin
L Duvillié
E Calvo
机构：
[1] Massachusetts General Hospital Cancer Center,Division of Hematology and Oncology
[2] and Harvard Medical School,undefined
[3] Phase I Clinical Trials Program,undefined
[4] Henry Ford Hospital,undefined
[5] 2799 West Grand Boulevard,undefined
[6] Institut de Cancerologie de l'Quest—Rene Gauducheau,undefined
[7] Saint Herblain,undefined
[8] START Madrid,undefined
[9] Centro Integral Oncológico Clara Campal,undefined
[10] Hospital Madrid Norte-Sanchinarro,undefined
[11] Oncology Clinical Statistics,undefined
[12] Pfizer Inc,undefined
[13] Oncology Clinical Development,undefined
[14] Pfizer Inc,undefined
[15] 10 Fawcett Street,undefined
[16] Suite 2013,undefined
[17] Oncology Late Phase Strategy Development,undefined
[18] Pfizer Global Research and Development,undefined
[19] Oncology Clinical Development,undefined
[20] Pfizer Global Research and Development,undefined
来源：
British Journal of Cancer | 2014年 / 111卷
关键词：
bosutinib; capecitabine; neoplasms; metastatic cancer; phase 1; safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2058 / 2066
页数：8
相关论文
共 50 条
  • [21] Phase Ib dose-escalation study of eribulin in combination with capecitabine in patients with advanced/metastatic cancer
    Savulsky, C.
    Nasim, M.
    Plummer, R.
    Evans, J.
    Morrison, R.
    Anthoney, A.
    Haney, S.
    Madi, A.
    Johnston, C.
    Carter, D.
    Reydermann, L.
    Gopalakrishna, P.
    Wanders, J.
    Twelves, C.
    ONKOLOGIE, 2012, 35 : 153 - 154
  • [22] A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
    Li, Xiaoyu
    Qiu, Meng
    Wang, ShengJun
    Zhu, Hong
    Feng, Bi
    Zheng, Li
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (03) : 593 - 604
  • [23] A phase I dose-escalation study of the novel peptide ALM201 in patients (pts) with advanced solid tumours
    El-Helali, A.
    Plummer, R.
    Jayson, G.
    Coyle, V.
    Drew, Y.
    Mescallado, N.
    Harris, N.
    Clamp, A.
    McCann, J.
    Kennedy, R.
    Cranston, A.
    Wilson, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [24] A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
    Xiaoyu Li
    Meng Qiu
    ShengJun Wang
    Hong Zhu
    Bi Feng
    Li Zheng
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 593 - 604
  • [25] Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours
    Kitzen, J. J. E. M.
    de Jonge, M. J. A.
    Lamers, C. H. J.
    Eskens, F. A. L. M.
    van der Biessen, D.
    van Doorn, L.
    ter Steeg, J.
    Brandely, M.
    Puozzo, Ch.
    Verweij, J.
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (10) : 1764 - 1772
  • [26] A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors
    Amarantidis, K.
    Houhouli, K.
    Papatheodorou, K.
    Miloussis, A.
    Matthaios, D.
    Chatzaki, E.
    Lyrantzopoulos, N.
    Tsaroucha, A.
    Tentes, A.
    Kakolyris, S.
    ONCOLOGY RESEARCH, 2006, 16 (06) : 281 - 287
  • [27] A dose escalation study of docetaxel plus capecitabine in combination with oxaliplatin in patients with advanced solid tumors
    Amarantidis, Kyriakos
    Xenidis, Nikolaos
    Chelis, Leonidas
    Chiotis, Anestis
    Tentes, Apostolos
    Chatzaki, Ekaterini
    Kortsaris, Alexandros
    Polychronidis, A.
    Karakitsos, Petros
    Kakolyris, Stylianos
    ACTA ONCOLOGICA, 2010, 49 (02) : 245 - 251
  • [28] PHARMACOKINETICS OF ERIBULIN MESILATE IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH ADVANCED/METASTATIC CANCER: RESULTS FROM A PHASE IB DOSE-ESCALATION STUDY
    Twelves, C. J.
    Nasim, M.
    Anthoney, A.
    Cresti, N.
    Savulsky, C.
    Johnston, C.
    Reyderman, L.
    Wanders, J.
    Plummer, R.
    Evans, T. R. J.
    ANNALS OF ONCOLOGY, 2012, 23 : 129 - 129
  • [29] A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer
    Nasim, Muhammad Yaser
    Plummer, Ruth
    Evans, T. R. Jeffry
    Morrison, Rosemary
    Anthoney, David Alan
    Haney, Sophie
    Madi, Ayman
    Savulsky, Claudio Isaac
    Johnston, Claire
    Carter, David
    Reyderman, Larisa
    Gopalakrishna, Prashanth
    Wanders, Jantien
    Twelves, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer.
    Leong, S.
    Camidge, R.
    Eckhardt, G.
    Basche, M.
    Musib, L.
    Darstein, C.
    Thornton, D.
    Britten, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 91S - 91S
12345